X0609 4 2026-09-01 false 0001088856 CORCEPT THERAPEUTICS INC CORT 0002150104 Vieira Roberto Wandenkolk false C/O CORCEPT THERAPEUTICS INCORPORATED 101 REDWOOD SHORES PARKWAY REDWOOD CITY CA 94065 false true false false President, Oncology true Common Stock 2026-09-01 4 A false 138 113.38 A 4206 D Common Stock 2026-09-01 4 A false 138 0.00 A 4344 D Common Stock 2026-09-02 4 F false 102 113.38 D 4242 D Common Stock 2026-09-02 4 M false 58333 21.63 A 62575 D Common Stock 2026-09-02 4 S false 23600 109.3506 D 38975 D Common Stock 2026-09-02 4 S false 23770 110.7004 D 15205 D Common Stock 2026-09-02 4 S false 1537 111.3733 D 13668 D Common Stock 2026-09-02 4 S false 974 112.3966 D 12694 D Common Stock 2026-09-02 4 S false 1606 113.7187 D 11088 D Common Stock 2026-09-02 4 S false 5621 114.5779 D 5467 D Common Stock 2026-09-02 4 S false 1225 115.4395 D 4242 D Stock option (right to buy) 21.63 2026-09-02 4 M false 58333 0.00 D 2034-02-01 Common Stock 58333 141667 D The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. Includes 199 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. The closing price on September 1, 2026 was used to calculate the withholding obligation. Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the time of this transaction. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $108.97 to $109.83 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.06 to $111.03 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.06 to $111.945 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.08 to $113.03 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.11 to $114.09 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.24 to $115.195 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.255 to $115.57 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on January 29, 2028, subject to the Reporting Person's continued service. The power of attorney under which this form was signed is on file with the Commission. /s/ Joseph Douglas Lyon, as attorney-in-fact for Roberto Wandenkolk Vieira 2026-09-03